| Primary |
| Chronic Obstructive Pulmonary Disease |
46.8% |
| Hypertension |
17.0% |
| Diabetes Mellitus |
7.4% |
| Cystic Fibrosis |
6.4% |
| Prophylaxis |
4.3% |
| Amnesia |
2.1% |
| Dyslipidaemia |
2.1% |
| Hyperlipidaemia |
2.1% |
| Myocardial Ischaemia |
2.1% |
| Osteoporosis |
2.1% |
| Anticoagulant Therapy |
1.1% |
| Cardiac Failure |
1.1% |
| Haemorrhage |
1.1% |
| Heart Valve Replacement |
1.1% |
| Hypothyroidism |
1.1% |
| Tachycardia |
1.1% |
| Type 2 Diabetes Mellitus |
1.1% |
|
| Chronic Obstructive Pulmonary Disease |
12.5% |
| Angina Unstable |
8.3% |
| Atrial Flutter |
8.3% |
| Chest Discomfort |
8.3% |
| Sudden Death |
8.3% |
| Tachyarrhythmia |
8.3% |
| Acute Myocardial Infarction |
4.2% |
| Alanine Aminotransferase Increased |
4.2% |
| Angina Pectoris |
4.2% |
| Benign Prostatic Hyperplasia |
4.2% |
| Excoriation |
4.2% |
| Herpes Zoster |
4.2% |
| Lung Disorder |
4.2% |
| Myocardial Ischaemia |
4.2% |
| Respiratory Failure |
4.2% |
| Syncope |
4.2% |
| Troponin I Increased |
4.2% |
|
| Secondary |
| Product Used For Unknown Indication |
50.0% |
| Cystic Fibrosis |
20.0% |
| Adjuvant Therapy |
10.0% |
| Lung Adenocarcinoma |
10.0% |
| Chronic Hepatitis B |
5.0% |
| Rheumatoid Arthritis |
5.0% |
|
| Chest Discomfort |
25.0% |
| Cold Sweat |
12.5% |
| Erythema Multiforme |
12.5% |
| Pemphigus |
12.5% |
| Pneumonia |
12.5% |
| Rash Pruritic |
12.5% |
| Sepsis |
12.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.1% |
| Rheumatoid Arthritis |
24.7% |
| Drug Use For Unknown Indication |
9.8% |
| Prophylaxis |
4.8% |
| Chronic Obstructive Pulmonary Disease |
4.7% |
| Hypertension |
4.1% |
| Gastritis Prophylaxis |
2.7% |
| Osteoporosis |
2.7% |
| Hepatic Function Abnormal |
2.4% |
| Hepatic Neoplasm Malignant |
2.2% |
| Non-small Cell Lung Cancer |
2.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.9% |
| Infection Prophylaxis |
1.7% |
| Upper Respiratory Tract Inflammation |
1.7% |
| Liver Disorder |
1.4% |
| Diabetes Mellitus |
1.3% |
| Acute Coronary Syndrome |
1.0% |
| Pain |
0.9% |
| Prophylaxis Of Nausea And Vomiting |
0.9% |
| Supplementation Therapy |
0.9% |
|
| Pyrexia |
21.2% |
| Pneumonia |
8.2% |
| Rheumatoid Arthritis |
8.2% |
| Tuberculous Pleurisy |
7.1% |
| Anaphylactic Reaction |
5.9% |
| Cerebral Haemorrhage |
5.9% |
| Blood Bilirubin Increased |
4.7% |
| Diabetes Mellitus |
4.7% |
| Drug Interaction |
4.7% |
| Dysgeusia |
3.5% |
| Dyspnoea |
3.5% |
| Pruritus |
3.5% |
| Bronchospasm |
2.4% |
| Cerebrovascular Accident |
2.4% |
| Fall |
2.4% |
| Haematemesis |
2.4% |
| Hypotension |
2.4% |
| Lung Infection |
2.4% |
| Progressive Multifocal Leukoencephalopathy |
2.4% |
| Respiratory Failure |
2.4% |
|
